Put Yourself In The CEO’s Shoes: Audience Makes Drug Pricing And Investment Decisions At EHFG
A pricing simulation exercise at the recent EHFG conference gave delegates an idea of the multiple factors that have to be taken into account when setting the price of a new drug for a rare disease – and deciding which candidate molecules are worth investing in.
You may also be interested in...
Celgene, which continues to plough back a very high proportion of its revenues into R&D, remains the preferred partner of choice for biotechs who hope to bring the next wave of innovative products to the market, Kevin Loth, VP of corporate affairs and policy in Europe tells Scrip.
In a wide-ranging discussion at the recent European Health Forum Gastein, policy makers explored big-picture challenges and ideas of what governments should do to ensure access to increasingly expensive medicines as pressures grow on national health care systems.
From next year, more agencies will be involved in the UK’s regulatory reliance procedure for new drug approvals, which was first introduced in 2021 to allay fears of post-Brexit delays to UK applications. The pharmaceutical industry said it looked forward to working with the regulator on the new framework.